Crowdonomics
All companies
CERN Corporation logo

CERN Corporation

Operating

Cern Corporation

Healthcare · Coto de Caza, CA · Founded 2016

Microbicidal light treatment for fungal & bacterial vaginosis

Post-money valuation ⓘ
$12.4M
As of Apr 2023 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$370,399
Across 1 round since 2022
Latest share price
$0.80
Reg CF · Common Stock · Sep 2022 offering price

Financials

FY2020–FY2023 · from SEC filings · hover any figure for its source
$0
−$74K
2020
$0
2021
$0
−$112K
2022
$0
−$221K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed*
FY2021 reviewed*
FY2022 unaudited
FY2023 unaudited
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$111,343
$220,573
Net income
-$73,704
$0
-$111,759
-$220,637
Taxes paid
$0
$0
$0
$2,123
Balance sheet
Cash
$8,834
$8,964
$219,757
$173,972
Accounts receivable
$0
$0
$0
$0
Total assets
$8,834
$8,964
$219,757
$173,972
Short-term debt
$139,896
$34,093
$84,546
$84,682
Long-term debt
$0
$37,207
$84,546
$84,682
Total liabilities
$139,896
$71,300
$169,091
$169,364
Other
Headcount
—
1
1
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$12.0M
pre-money
Reg CF · Common · Sep 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Raised $370.4K / $1.1MInvestors 72Post-money $12.4M

Team

8 people
Gregg A. Klang
CEO, President and Founder

Founder/Inventor of the Cern Device™. Gregg’s background is principally in business and marketing, with most of his career in technical sales and marketing for a Fortune 50 organization. Gregg has senior management experience, an extensive background in global sales and account management, and extensive training through the Boston Consulting Group. His interest in life sciences has generated multiple patents in the medical device space. In the summer of 2019, Cern Corp. was nominated to participate in the LA-BioStart program for CEOs who are bringing novel and disruptive technologies within the life sciences vertical to market. Education: MBA Pepperdine University, BA Economics University California, Irvine. Greg works full-time Cern.

Dr. Melanie Santos, MD FACOG, FPMRS
Chief Medical Officer

Dr. Santos is a Urogynecology & Reconstructive Pelvic Surgery Specialist in Fullerton, CA with over 17 years of experience in the medical field. Dr. Santos graduated from Albert Einstein College of Medicine of Yeshiva University Medical School in 2004. She completed her residency in Obstetrics and Gynecology at Stanford University, followed by fellowship training for Pelvic Reconstructive Surgery at Emory University. She is affiliated with St. Jude Medical Center, within the Providence St. Joseph Healthcare system. Dr. Santos is Medical Director of Pelvic Health at St. Jude and on executive and national advisory boards for the Providence St. Joseph Women and Children's Institute, while also performing clinical work at St. Jude Heritage Women’s Center in Orange County California. Dr. Santos has considerable experience working in the medical device and pharma area as she consults to various entities and is a key-note speaker internal to Providence Health being responsible for communications with GYN related practitioners within the organization. She is also an advocate for women in medicine, developing the Women Physicans Group at her hospital as well as an annual summit for women in healthcare. Melanie works part-time on Cern (5 hours/week on Cern).

Todd Peterson, PhD
Chief Science Advsior

Dr. Todd Peterson is the Founder and Principal of GenApex Bio, a life sciences advisory, investment, and board practice company based in Coronado, California. With over 35 years across academic research and industrial R&D, spanning molecular genetics, genomics, cell biology and synthetic biology engineering, his experience encompasses biotechnology, clinical diagnostics, life science research tools, drug discovery and industrial biotechnology markets, products, and technologies. Prior to GenApex Bio, Dr. Peterson was Chief Scientific Officer at the Allen Institute comprising foundational and applied research programs across its Brain Science, Cell Science, Immunology Institutes, and the Paul G. Allen Frontiers Group. Prior to the Allen Institute, Dr. Peterson was Chief Technology Officer at Synthetic Genomics (SGI) where he led an integrated team of scientists, engineers and informaticians to engineer diverse complex living systems. Before joining SGI, he led Synthetic Biology, Cloning and Protein Expression and Genomics R&D at Invitrogen/Life Technologies (now ThermoFisher), a global leader in life science research tools. Dr. Peterson has held industrial R&D leadership and bench scientist positions with increasing responsibilities at Genicon Sciences, Trega Biosciences, Hybritech, Gen-Probe and Immulok, focusing on technology development and product commercialization. Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne, Germany, received his Ph.D. in Microbiology at the University of Southern California School of Medicine, and received his M.A. in Biological Sciences and his B.A. in Molecular Biology and Biochemistry from the University of California, Santa Barbara. Todd works part-time on Cern (5 hours/week).

Hyunsook Park, PhD
Director of Microbiology

Dr. Park is a Professor of Microbiology at California State University Los Angeles and has over twenty years of research experience on fungal pathogenesis. As a first-generation immigrant and a woman scientist, her research is naturally geared toward the direction of making a profound impact on improving women’s health. Using C. albicans as a model fungal pathogen, Dr. Park studied how human fungus recognizes the host environmental changes and initiates infection from a part of the normal microbiome. She also studied developing a combination therapy to overcome the limitation of the current antifungal agents to treat oral and vaginal candidiasis.Positions and Education: 2008 – Current, California State University, Los Angeles, 2002 – 2007, Fungal Pathogenesis Research Group at Harbor-UCLA Medical Center, 1998-2002. Ph.D. in Microbiology at Ewha Womans University, Korea. Hyunsook works part-time on Cern (20 hours/week on Cern).

Annette M. Walker
Board of Directors

Annette’s current position is President, City of Hope Orange County. An experienced healthcare executive with decades of experience that includes broad roles such as the President of Strategy for Providence St. Joseph Health, the third largest provider organization in the country. Annette has twice been recognized as one of the “Top 100” people in US Healthcare Modern Healthcare, the industry's leading trade journal. In her position at City of Hope, she is responsible for the development of an academic campus that will be Orange County, California's most advanced cancer prevention, treatment and research OP center and hospital. Annette is a solutions architect and nationally recognized strategist, thought leader and author/keynote speaker on transforming the health care industry.

Dr. David C. Lagrew
Board of Directors

Chief of Service, Maternal Fetal Medicine at Hoag Hospital, Newport Beach, California. Past positions include Executive Medical Director, Women's Services at Providence St. Joseph Health where he manages development of the Ministry's Centers of Excellence and regional Clinical Institute of Women's Health within St. Joseph’s/Providence Health. David’s background also includes extensive executive experience having held the position of Medical Director at Long Beach Memorial as well as Medical Director, Women’s Services at Saddleback Memorial Medical Center prior to his appointment as Executive Director, Women’s Services at St. Joseph’s. David has recently retired from over 35 years of clinical practice and is regarded as a thought leader within the industry. David works part-time on Cern (2 hours/week).

Dr. Jack Sobel
Key Advisor

Dr. Sobel is a consulting Physician, Clinical Advisor, and one of the world’s foremost authorities on infectious diseases of the GYN tract. Dr. Sobel is a widely published and strongly funded physician-researcher. He has been involved in basic science, translational and clinical research since the inception of his Infectious Diseases Research Fellowship in 1976 at the NIH Laboratory of Clinical Investigation. He has served as a consultant for the U.S. Centers for Disease Control and Prevention’s special committee for recommending guidelines for the treatment of sexually transmitted disease. He has served as President of the Michigan Infectious Diseases Society from 1997 to 1999, a Member of the Infectious Diseases Society of America, and the National State President’s Committee and the Infectious Diseases Society of America, Practice Guidelines Committee. Jack works part-time on Cern (1 hour/week).

Vern Roohk, PhD
PhD, Physiology

Vern Roohk received his PhD in Physiology and Biochemistry from UC Davis in 1971 and did post-doctoral stints in bioengineering at USC and UCLA over the next few years. He has clinical experience as an ECMO (Extracorporeal Membrane Oxygenation) team member and lab supervisor with the original NIH-funded life-support team at UCI from the mid 1970s. Since then Dr. Roohk has served as lab director and/or IACUC chair for a number of both university and private pre-clinical testing facilities. Dr. Roohk has spent over 50 years in physiology associated with the development and testing of medical devices. Dr. Roohk co-founded American ImmunoTech, LLC, and Vestara in Costa Mesa, CA, which conducted sepsis research utilizing ultraviolet technology in an extracorporeal circuit. Dr Roohk is a recognized expert in Animal Physiology, and in vivo testing. Vern works part-time on Cern (2 hours/week).

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 4 annual reports (FY2022–FY2025)

72 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRMay 29, 20240001942093-24-000002
    EDGAR
  • Form C-ARMay 29, 20240001942093-24-000001
    EDGAR
  • Form C-UMay 2, 20230001665160-23-001162
    EDGAR
  • Form C-ARApr 27, 20230001665160-23-000917
    EDGAR
  • Form C/AFeb 15, 20230001665160-23-000253
    EDGAR
  • Form C/ADec 12, 20220001665160-22-003055
    EDGAR
  • Form CSep 15, 20220001665160-22-002403
    EDGAR
Source: ManualCIK 0001942093DEShare price $0.80

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.